Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels

Kidney Int. 1991 Feb;39(2):259-65. doi: 10.1038/ki.1991.31.

Abstract

The contractile properties of recombinant human erythropoietin (rHuEPO) on isolated resistance vessels of renal and mesenteric vascular beds were studied in an in vitro model using a small vessel myograph. Under isometric conditions, rHuEPO caused a contraction of this vasculature in a concentration range between 10 U/ml and 200 U/ml. A maximal active wall tension of 1.52 +/- 0.19 mN/mm was obtained under a rHuEPO dose of 200 U/ml. In Ca2+ free solution, the pressor response to high rHuEPO-concentrations was attenuated, and the response to low rHuEPO concentrations was abolished. In the presence of verapamil, phentolamine and saralasin, rHuEPO-induced contractions were not affected significantly. A dose-dependent vasodilatation of mounted vasculature to acetylcholine (ACh) indicated that endothelium remained intact in our preparations. rHuEPO-induced vessel contraction was not abrogated after an enzymatical removal of endothelium by collagenase, confirming that the described contractile responses are endothelial independent. These findings suggest that a direct vasopressor effect of rHuEPO on proximal resistance vessels may contribute to development of hypertension seen in rHuEPO-treated hemodialysis patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Dose-Response Relationship, Drug
  • Erythropoietin / adverse effects
  • Erythropoietin / pharmacology*
  • Humans
  • Hypertension / etiology*
  • In Vitro Techniques
  • Kidney / blood supply*
  • Male
  • Muscle, Smooth, Vascular / drug effects*
  • Rats
  • Rats, Inbred WKY
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / pharmacology
  • Vascular Resistance / drug effects*
  • Vasoconstriction / drug effects*

Substances

  • Recombinant Proteins
  • Erythropoietin